Category Archives: Health

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

LUCID: music, medicine, and machine learning

In this interview, News-Medical speaks to Zoë Thomson, Co-founder and Chief Innovation Officer of LUCID, about how music and machine learning are changing how we approach mental and neuropsychiatric health.

Study examines the cost-effectiveness of AI-supported detection of proximal caries

The Interactive Talk presentation, “Artificial Intelligence and non-/micro-invasive was cost-effective in a Randomized Trial”, will be presented by Falk Schwendicke, Charite – Universitaetsmedizin Berlin, Germany and take place on Saturday, June 25th, 2022 at 2 p.m. China Standard Time (UTC+08:00) during the “e-Oral Health Network I” session.